ING Groep NV Grows Stake in IDEXX Laboratories, Inc. $IDXX

ING Groep NV grew its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 3,319.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 11,491 shares of the company’s stock after purchasing an additional 11,155 shares during the quarter. ING Groep NV’s holdings in IDEXX Laboratories were worth $7,774,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Virtus Advisers LLC acquired a new stake in shares of IDEXX Laboratories during the third quarter worth $26,000. Park Place Capital Corp acquired a new stake in shares of IDEXX Laboratories during the fourth quarter worth $29,000. WealthCollab LLC acquired a new stake in shares of IDEXX Laboratories during the second quarter worth $30,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of IDEXX Laboratories during the third quarter worth $36,000. Finally, Mowery & Schoenfeld Wealth Management LLC lifted its stake in shares of IDEXX Laboratories by 58.8% during the fourth quarter. Mowery & Schoenfeld Wealth Management LLC now owns 54 shares of the company’s stock worth $37,000 after buying an additional 20 shares during the period. 87.84% of the stock is owned by hedge funds and other institutional investors.

IDEXX Laboratories Stock Down 0.2%

Shares of NASDAQ IDXX opened at $561.17 on Tuesday. IDEXX Laboratories, Inc. has a 12-month low of $506.91 and a 12-month high of $769.98. The stock has a market cap of $44.27 billion, a PE ratio of 41.32, a P/E/G ratio of 3.08 and a beta of 1.55. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19. The company has a 50-day moving average of $562.81 and a 200 day moving average of $631.11.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.41 by $0.06. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The company had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.12 billion. During the same quarter in the prior year, the company earned $2.91 EPS. IDEXX Laboratories’s revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, sell-side analysts predict that IDEXX Laboratories, Inc. will post 14.68 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on IDXX. Weiss Ratings downgraded shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 11th. Stifel Nicolaus lowered their target price on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research note on Tuesday, March 31st. Citigroup initiated coverage on IDEXX Laboratories in a research note on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 target price on the stock. Piper Sandler decreased their price target on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a report on Monday, February 9th. Finally, UBS Group lowered their price objective on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 28th. Seven research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $751.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.